Obsession beats Avengers: Endgame by day 25, despite a sub-$1M budget

Obsession, the micro-budget horror sensation, has outgrossed Avengers: Endgame on its 25th day of release, and Collider is pointing to this as an almost unbelievable turn of box-office fate. The movie is now trending above Avengers: Endgame as it completes one month of release, turning what should be a niche, low-expectation play into a headline-level performer.

The numbers behind the surprise are doing the heavy lifting. Obsession cost less than $1 million to produce, was picked up for domestic distribution by Focus Features for a reported $15 million after its premiere at the Toronto International Film Festival in 2025, and then opened to excellent reviews and audience response on May 15. Since then it has grossed more than $150 million domestically and more than $200 million worldwide. On day 25, it has already shown a kind of staying power that typically belongs to much bigger studio event films, not a production with a sub-$1M price tag.

If you are an operator or investor trying to model theatrical performance, this is the part that matters: the path from “micro-budget” to “national and global audience pull” often feels too messy to underwrite. But Obsession’s trajectory suggests that the market can still reward films that start with credibility rather than scale. The source links its momentum to excellent reviews and audience response, which is basically the theatrical equivalent of an early-demand signal. When those signals come through quickly, the distribution and marketing machine often has less to “convince” and more to “keep up.”

There is also a clear capital and incentive story underneath the hype. Focus Features paid a reported $15 million for domestic distribution after TIFF 2025. That means this is not a zero-stakes gamble; it is a targeted bet on a specific title after a high-visibility industry stop. On a sub-$1M production cost base, a $15 million distribution acquisition can still be positioned as a high-upside trade, because the downside is capped relative to bigger-budget films where the break-even math can get brutally unforgiving.

The article also anchors Obsession against the Marvel track record, and it does it in a way that underscores how unusual this moment is. It notes that Obsession has outgrossed the least successful Marvel Cinematic Universe movie, which is identified as The Marvels. But it also keeps expectations grounded: Obsession is nowhere near the ballpark occupied by some of the MCU’s biggest hits. That distinction is important for boards and finance teams. It prevents the wrong takeaway, which would be “small films will always beat event films.” Instead, it suggests something more precise: when costs are low and audience pull shows up early, the early-to-mid run can become disproportionately powerful, even without matching the absolute ceiling of franchise juggernauts.

There are second-order implications for media strategy here, especially around greenlighting and portfolio thinking. When a film like this breaks out, it strengthens the case for backing releases where the cost curve is favorable and the demand curve can be amplified by reviews and word-of-mouth. It also changes the internal debate about how much you should lean on scale versus audience signal. In practical terms, executives may be more willing to fund theatrical marketing and distribution for films that can credibly generate momentum rather than relying entirely on production scale.

Finally, this is a competitive wake-up call for peers. If a micro-budget horror title can cross $150 million domestically and more than $200 million worldwide while also surpassing Avengers: Endgame in the first 25 days, it pressures everyone who assumes theatrical dominance is reserved for big-budget franchises. The stakes are not just box office trivia. They are about how distribution budgets get allocated, how risk is priced, and whether boards continue to treat “audience response” as a soft factor instead of a measurable driver of run rate.